A5102810881- Hippo pathway signaling and YAP/TAZ
- Developmental Biology and Gene Regulation
- Melanoma and MAPK Pathways
- Wnt/β-catenin signaling in development and cancer
- PI3K/AKT/mTOR signaling in cancer
- Synthesis and biological activity
- Beetle Biology and Toxicology Studies
- Computational Drug Discovery Methods
- Chromatin Remodeling and Cancer
- Cancer Mechanisms and Therapy
- Genomics and Chromatin Dynamics
- Click Chemistry and Applications
- Enzyme function and inhibition
La Trobe University
2018-2023
Peter MacCallum Cancer Centre
2017-2023
Sydney Hospital
1971
The University of Sydney
1971
Twenty patients with metastatic malignant melanoma were treated a new cytotoxic agent, 5-(dimethyltriazeno) imidazole-4-carboxamide, in doses of 4.5 mg/kg body weight, daily for 10 days. An objective remission was observed 4 out 20 following the first course. No remissions subsequent courses. Toxic effects minimal. Further evaluation use this drug treatment appears justified.
The SWI/SNF ATP-dependent chromatin-remodeling complex is an important evolutionarily conserved regulator of cell cycle progression. It associates with the Retinoblastoma (pRb)/HDAC/E2F/DP transcription to modulate cycle-dependent gene expression. key catalytic component in mammals ATPase subunit, Brahma (BRM) or BRG1. BRG1 was previously shown be phosphorylated by G1-S phase regulatory kinase Cyclin E/CDK2 vitro, which associated bypass G1 arrest conferred However, it unknown whether direct...
In both Drosophila melanogaster and mammalian systems, epithelial structure underlying cell polarity are essential for proper tissue morphogenesis organ growth. Cell interfaces with multiple cellular processes that regulated by the phosphorylation status of large protein networks. To gain insight into molecular mechanisms coordinate growth, we screened a boutique collection RNAi stocks targeting kinome their capacity to modify "cell polarity" eye wing phenotypes. Initially, identified kinase...
Elevated Ras signalling is highly prevalent in human cancer; however, targeting Ras-driven cancers with pathway inhibitors often leads to undesirable side effects and drug resistance. Thus, identifying compounds that synergise would enable lower doses of the be used also decrease acquisition Here, a specialised chemical screen using Drosophila model cancer, we have identified reduce tumour size by synergising sub-therapeutic inhibitor trametinib, which targets MEK, mitogen-activated protein...
Abstract The RAS oncogene and upregulation of the signalling pathway is highly prevalent in human cancer, therefore, therapeutically targeting a common treatment cancer. However, not sufficient to drive malignant since senescence mechanisms prevent cancer progression. Thus, additional mutations, such as mutations that or alter tissue architecture (cell polarity), are required for -driven tumour Moreover, cancers with inhibitors can often lead undesirable side-effects drug resistance....